Received May 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | M4B34 | — |
Late 2nd and 3rd dose/received 1st dose on 13-Nov-2024, 2nd one not until 26-Apr-2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 40-year-old female patient who received HAB (Twinrix) (batch number M4B34) for prophylaxis. Previously administered products included Twinrix (received 1st dose on 13th November 2024 of lot number H7RF2). On 26-APR-2025, the patient received the 2nd dose of Twinrix. On 26-APR-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late 2nd and 3rd dose/received 1st dose on 13-Nov-2024, 2nd one not until 26-Apr-2025). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 07-MAY-2025 A registered pharmacist called and reported a question on the Twinrix vaccine dosing schedule, so the patient received her 1st dose on 13th November 2024, her 2nd one not until 26th April 2025, so the reporter was unsure about when she needs her 3rd dose. The vaccine administration facility was the same as primary reporter. The patient received 2nd dose of Twinrix later than the recommended interval, which led to lengthening of vaccine schedule.